CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Wayne Paterson

Vice Chairman and Chief Executive Officer, Anteris Technologies Global Corp.

Search every verified Wayne Paterson interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Wayne Paterson, Vice Chairman and CEO of Anteris Technologies, has recently discussed the company’s progress in developing DurAVR, a transcatheter heart valve for treating aortic stenosis. In May 2026, he announced the enrollment and treatment of the first U.S. patients in the global PARADIGM pivotal trial, conducted at Montefiore Medical Center in New York. Paterson described the milestone as the culmination of a nine-year development process and highlighted the valve’s design as a single-piece, biomimetic device intended to replicate natural valve anatomy and flow. He also cited clinical data, including mean gradients and laminar flow measurements, which he said differentiate DurAVR from existing products on the market. In earlier appearances, Paterson discussed a $200 million public offering and a private placement agreement with Medtronic, which he characterized as a partnership and equity stake. He also noted the company’s progress in qualifying over 70 trial sites across the U.S. and Europe and mentioned ongoing data presentations, including a reported 3% patient-prosthesis mismatch rate for DurAVR compared to about 30% for the market leader. Paterson has consistently framed aortic stenosis as a fatal disease with no pharmacotherapy and positioned Anteris’s valve as a potential alternative to established TAVR devices, while acknowledging the company’s need for capital to fund clinical development and manufacturing scale-up.

Recent appearances

  • Beyond Aortic Valve Replacement: Understanding Flow Dynamics and the Role of DurAVR THV

    May 11, 2026 · 📺 MedInsights Unleashed

    In this episode of MedInsights Unleashed, Wayne Paterson, Vice Chairman and CEO of Anteris Technologies, joins us to discuss one of the fastest evolving areas in structural heart disease — whether the future of valve replacement lies not only in replacing diseased valves, but also in restoring more natural heart flow. The discussion explores aortic stenosis, the evolution of TAVR, and the emerging science and MRI data surrounding DurAVR THV, including the potential importance of flow dynamics, laminar flow, durability, and long-term valve performance. We also discuss patient selection, f…

    Watch on YouTube ↗

  • Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve

    May 06, 2026 · 📺 Proactive Investors

    Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has reached a major milestone by enrolling and treating the first patients in the United States for its DurAVR Transcatheter Heart Valve global pivotal trial. These landmark procedures were conducted at the Montefiore Medical Center in New York and were specifically performed for patients diagnosed with severe calcific aortic stenosis. Paterson noted during the announcement that conducting these initial U.S. cases within the global PARADIGM Trial represents a significant achievement for t…

    Watch on YouTube ↗

  • Wall Street Said It Couldn't Be Done, We Did It Anyway with Wayne Paterson

    March 05, 2026 · 📺 This is Cruxx

    Wayne Paterson, CEO and Vice Chairman of Anteris Technologies, joins host Jordan Burgin for a frank conversation about pivoting a failing drug company into the structural heart space and building what may be medtech's next billion-dollar product. Wayne shares how 36 drug launches, a pharma-first lens on total disease management, and a blank sheet of paper led to the world's first biomimetic transcatheter heart valve and why the market's two dominant players never saw it coming. Key Topics How a 25-year pharma career became the unlikely blueprint for disrupting TAVR Building the first biomimet…

    Watch on YouTube ↗

  • Anteris Technologies announces $200M public offering to fund clinical growth

    January 22, 2026 · 📺 Proactive Investors

    Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has launched a proposed underwritten public offering of $200 million of its common stock, subject to market and other customary conditions. In connection with the offering, Anteris also plans to grant the underwriters a 30-day option to purchase up to an additional $30 million of common stock at the public offering price. Paterson also confirmed that Anteris has entered into a private placement agreement with Medtronic plc, further strengthening the company’s balance sheet and strategic po…

    Watch on YouTube ↗

  • Anteris Technologies secures Danish clearance for global PARADIGM trial of DurAVR® Valve

    October 22, 2025 · 📺 Proactive Investors

    Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to share a major milestone in the company’s development of DurAVR®, its groundbreaking aortic valve replacement technology designed to transform treatment for patients suffering from aortic stenosis — a fatal heart disease for which no pharmacotherapy options exist. Paterson explained that DurAVR® was designed from the ground up following extensive collaboration with leading cardiologists and cardiac surgeons. The result is a biomimetic, balloon-expandable valve engineered to replicate natural valve anatomy and physi…

    Watch on YouTube ↗

  • Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones

    May 16, 2025 · 📺 Proactive Investors

    Anteris Technologies Global Corp. CEO Wayne Paterson joined Steve Darling from Proactive to provide an update on the company’s progress during the first quarter of 2025, highlighting significant regulatory, clinical, and operational milestones following its successful $80 million initial public offering. A core focus of the quarter was the continued development of the company’s DurAVR® transcatheter heart valve (THV), a first-in-class device designed for patients with severe aortic stenosis. Approximately $20.8 million of the IPO proceeds have been allocated to advancing DurAVR®, including fu…

    Watch on YouTube ↗

  • Next generation of heart valves, with Anteris CEO Wayne Paterson

    May 04, 2025 · 📺 Frazis Capital Partners

    Wayne Paterson joins Michael Frazis to talk Anteris Technologies and revolutionising heart valve replacement Keywords Anteris, DurAVR™, structural heart, aortic stenosis, TAVI, medtech, heart valve innovation, clinical trials, biomechanics, U.S. FDA, commercialization, cardiac surgery, patient outcomes, investor interest, competitive differentiation, native-like valve, regulatory pathway, minimally invasive, biotech investment, cardiovascular innovation

    Watch on YouTube ↗

  • How an artful pivot and IPO is positioning Anteris Technologies to take on the red hot TAVR space

    February 26, 2025 · 📺 DeviceTalks

    In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that’s approaching the complicated and competitive TAVR market. Chris Newsmaker and Host Tom Salemi also discuss this week’s Newmarker’s Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA. This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the De…

    Watch on YouTube ↗

  • Anteris Technologies CEO Wayne Paterson Speaks With JustStocks Following $30 Million Capital Raise

    July 30, 2024 · 📺 JustStocks

    Anteris Technologies Ltd (ASX:AVR) CEO Wayne Paterson speaks with JustStocks Video following news of a $30 million placement to new and existing institutional and sophisticated investors.

    Watch on YouTube ↗

  • Anteris Technologies 2024 AGM: CEO Presentation by Wayne Paterson

    June 07, 2024 · 📺 Anteris Technologies

    Anteris Technologies CEO, Wayne Paterson presents at the Annual General Meeting (AGM) held on the 29th May 2024 in Sydney. Discover how Anteris Technologies plans to bring its highly differentiated, first in class (biomimetic) valve to market, to benefit aortic stenosis patients. Anteris Technologies proudly stands as Australia’s first and only structural heart company dedicated to transcatheter aortic valve replacement (TAVR). Our commitment to scientific advancement drives us to lead the charge in addressing critical challenges encountered by physicians and patients through pioneering re…

    Watch on YouTube ↗

  • Exclusive Post-AGM Interview with Anteris CEO Wayne Paterson on Ausbiz

    May 29, 2024 · 📺 Anteris Technologies

    Watch Wayne Paterson, CEO of Anteris Technologies (ASX: AVR), in an exclusive interview with Juliette Daly on ‪@ausbizTV‬. Wayne highlights key developments from the recent AGM, including an update on the planned DurAVR™ THV pivotal study (phase 3) and the company’s strategic direction for the next 12 months. Discover how Anteris Technologies plans to bring its highly differentiated, first in class (biomimetic) valve to market to benefit aortic stenosis patients. #asx #asxavr #avr #anteris #duravr #biotechstocks #medtech #aorticstenosis

    Watch on YouTube ↗

  • Anteris Technologies CEO Talks JustStocks Through 2024 Milestones Following $23 Million Raise

    April 15, 2024 · 📺 JustStocks

    Anteris Technologies Ltd (ASX: AVR) CEO Wayne Paterson speaks with JustStocks soon after announcing the completion of a $23 million placement. The company’s lead product, DurAVR, is a transcatheter heart valve for treating aortic stenosis. It has so far been implanted in 50 patients. Paterson says the clinical results to date demonstrate this new class of biomimetic valve outperforms the market leader. The additional capital will be put towards preparing for the DurAVR FDA pivotal study - a key step towards gaining regulatory clearance for the US market.

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →